公开(公告)号：US20230138752A1

公开(公告)日：2023-05-04

申请号：US17972972

申请日：2022-10-25

申请人： Purdue Research Foundation

发明人： Lynne Taylor ,  Clara Correa Soto

IPC分类号： A61K9/20 ,  A61K31/4418 ,  A61K31/439

摘要： The invention generally relates to plasticizers to improve release performance of amorphous solid dispersions. In certain aspects, the invention provides an amorphous solid dispersion (ASD) composition including a polymer, a high glass transition (Tg) active pharmaceutical agent (API), and a plasticizer.

公开(公告)号：US20230138003A1

公开(公告)日：2023-05-04

申请号：US18088045

申请日：2022-12-23

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Motoyuki TANAKA ,  Takashi KONDO ,  Yasuo HIROOKA ,  Taihei NISHIYAMA ,  Atsushi HIRAMATSU ,  Tomoyuki KODA ,  Sho KOUYAMA

IPC分类号： C07D471/04 ,  A61K31/444 ,  A61P43/00 ,  C07D401/14 ,  A61K9/20 ,  A61K31/519 ,  C07D487/04

摘要： A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.

公开(公告)号：US20230133044A1

公开(公告)日：2023-05-04

申请号：US17982233

申请日：2022-11-07

申请人： Dennis M. BROWN

发明人： Dennis M. BROWN

IPC分类号： A61K31/513 ,  A61K45/06 ,  A61K9/28 ,  A61K9/20 ,  A61K31/133 ,  A61K31/565 ,  A61K31/417

摘要： The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutic agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to mustard-based alkylating agents such as uracil mustard and analogs, derivatives, or prodrugs thereof, including 6-methyluracil mustard and 6-ethyluracil mustard.

公开(公告)号：US11638715B2

公开(公告)日：2023-05-02

申请号：US17842402

申请日：2022-06-16

申请人： Venatorx Pharmaceuticals, Inc.

发明人： Christopher J. Burns ,  Glen Coburn ,  Guo-Hua Chu ,  Stephen M. Condon ,  Steven A. Boyd ,  Daniel C. Pevear

IPC分类号： A61K31/7076 ,  A61K9/48 ,  C07H19/16 ,  C07H19/06 ,  C07F9/6561 ,  C07H19/10 ,  A61K31/53 ,  A61K31/7072 ,  A61K31/685 ,  A61K31/675 ,  A61K9/00 ,  A61K9/20 ,  C07D487/04

摘要： Described herein are orally-bioavailable nucleoside analogs and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of coronavirus infections, including SARS-CoV-2 infection.

公开(公告)号：US20230130628A1

公开(公告)日：2023-04-27

申请号：US18085372

申请日：2022-12-20

申请人： COSMO TECHNOLOGIES LTD.

发明人： Luigi MORO ,  Alessandro REPICI

IPC分类号： A61K49/00 ,  A61K9/28 ,  A61K9/20

摘要： Herein described are solid oral compositions of dyes for use in diagnostic endoscopy, preferably colon endoscopy.

公开(公告)号：US20230123099A1

公开(公告)日：2023-04-20

申请号：US17502322

申请日：2021-10-15

申请人： FERTIN PHARMA A/S

发明人： Helle WITTORFF

IPC分类号： A61K9/00 ,  A61K9/20 ,  A61K45/06

摘要： The invention relates to an oral chewable tablet suitable for improved mouthfeel, comprising dextrose in an amount from 50 to 95% by weight of the tablet; one or more active ingredients; and one or more binders, wherein the ratio between the one or more binders and dextrose is from 1:250 to 1:8.

公开(公告)号：US20230122949A1

公开(公告)日：2023-04-20

申请号：US18077085

申请日：2022-12-07

申请人： Mind Medicine, Inc.

发明人： Peter MACK ,  Timm TRENKTROG ,  Dustin MELTON ,  Bethany Amber DOTY ,  Jon SCHROEDER ,  Lisa Marie GARRETT

IPC分类号： A61K9/20 ,  A61K31/48 ,  A61K9/00

摘要： A solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet. A method of making a solid oral immediate release formulation of LSD by lyophilizing a flash frozen stock solution of LSD and excipients, including a non-gelling matrix former, filler, and binder in a pre-formed mold, and forming an orally disintegrating tablet. A method of treating an individual by administering a solid oral immediate release formulation of LSD, wherein the composition is produced by lyophilization of a feedstock in a pre-formed mold to form an orally disintegrating tablet and treating the individual.

公开(公告)号：US20230117397A1

公开(公告)日：2023-04-20

申请号：US17918791

申请日：2021-04-14

申请人： Excalibur Pharmaceuticals, Inc.

发明人： Estuardo Aguilar-Cordova ,  Laura Aguilar ,  José Agustín Rogelio Magaña Castro

IPC分类号： A61K31/4418 ,  A61P31/14 ,  A61P29/00 ,  A61K9/20

摘要： Provided herein are methods and uses involving pirfenidone pharmaceutical compositions (e.g., extended-release pirfenidone pills (e.g., tablets)) in treating COVID-19, treating and/or preventing viremia and/or viremia-induced disease caused by a virus, and/or an infection with a virus (e.g., DNA virus, RNA virus, for example, coronavirus (e.g., severe acute respiratory syndrome coronavims-2 (SARS-CoV-2) and variants thereof, severe acute respiratory syndrome-associated coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV)), in a subject (e.g., subject with COVID-19). Provided are methods of reducing elevated levels of one or more markers of inflammation (e.g., CRP, ferritin, LDH), inhibiting an inflammatory response (e.g., virus-induced) and/or inhibiting a cascade by one or more pro-inflammatory cytokines (e.g., TNF-α, IEN-γ, IL-Iβ, IL-6, IL-12) and/or in a subject (e.g., a subject with COVID-19 optionally having liver contraindications for pirfenidone).

公开(公告)号：US11628192B2

公开(公告)日：2023-04-18

申请号：US17082668

申请日：2020-10-28

申请人： Jiangnan University

发明人： Qixiao Zhai ,  Wei Chen ,  Huizi Tan ,  Wenwei Lu ,  Fengwei Tian ,  Jianxin Zhao ,  Hao Zhang

IPC分类号： A01N63/00 ,  A61K35/741 ,  A61P31/04 ,  A61P1/00 ,  A61K9/20 ,  A61K35/00

摘要： The disclosure discloses Bacteroides fragilis for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides fragilis CCFM1020 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of hosts infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides fragilis CCFM1020 for relieving endotoxin infection has broad application prospects.

公开(公告)号：US11628178B2

公开(公告)日：2023-04-18

申请号：US17686738

申请日：2022-03-04

申请人： Epalex Corporation

发明人： Steven L. Krill ,  Feng-Jing Chen ,  Michael A. Rogawski ,  Edward Brendan Magrab ,  Allen H. Heller

IPC分类号： A61K31/661 ,  A61K47/12 ,  A61K9/00 ,  A61K9/20

摘要： The present disclosure pertains to the use of fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof. Pharmaceutical compositions comprising fospropofol, pharmaceutically acceptable salts of fospropofol, or mixtures thereof, and methods of treating diseases or disorders, including migraine are also disclosed.